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Previewsthe reverse trancriptase inhibitor efavirenz
and by AMD3100, a drug that blocks HIV-
1 entry via the HIV-1 coreceptor CXCR4.
This suggests that the inflammatory
response to abortive HIV-1 infection is
triggered by premature termination of viral
DNA elongation, which signals caspase-1
and inflammasome activation and the
maturation and release of bioactive IL-1b
in these CD4+ T cells. Capsase-1 and
inflammasome activation are required
for IL-1b production in this system. There-
fore, caspase-1-dependent cell death,
known as pyroptosis, is a plausible mech-
anism of CD4 depletion.
DNA damage cascades also play a role
in death of activated CD4+ T cells that are
infected with HIV-1. Cooper et al. (2013)
demonstrated that virus-induced CD4+
T cell killing is triggered by integra-
tion. Cell death in this system was asso-
ciated with productive rather than abor-
tive infection. The mechanism of killing
following viral integration involved the
activation of DNA-dependent protein
kinase (DNA-PK), a central integrator of
the DNA damage response, which causes1000 Immunity 39, December 12, 2013 ª201phosphorylation of p53 and histone
H2AX.
Taken together, these studies high-
light the emerging complexity of innate
sensing of HIV-1, with multiple pathways
in different cell types leading to a variety
of outcomes. Lahaye and colleagues
speculate that enhancing innate sensing
might represent a strategy for enhancing
HIV-1 control and producing more effec-
tive vaccines. However, manipulation of
the innate sensing systems might also
result in increased pathogenesis. There-
fore, additional studies in this area
would be of significant value, particularly
in systems that allow interaction between
CD4+ T cells and other immune system
cells so that the total effects of such
manipulations on all cell types and
the overall immune response can be
determined.
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Activation of the complement system has long been known to be regulated by a series of steps involving fluid-
phase convertases. In this issue of Immunity, Liszewski et al. (2013) report the discovery of an intracellular
cathepsin-L-dependent C3 activation pathway.The complement system can be activated
by ‘‘hard-wired’’ pattern-recognition re-
ceptors (PRRs) that have evolved to
recognize pattern-associated molecular
patterns (PAMPs). PRRs in the comple-
ment system recognize exogenous and
endogenous ‘‘danger’’ motifs. Recogni-
tion receptors in the complement system
(i.e., specific antibody, mannan-binding
lectin [MBL], C1q, and natural immuno-
globulin M [IgM]) activate three separate
complement pathways referred to as the
classical, lectin, and alternative. Althougheach of these pathways is activated by
distinct PRRs, they all culminate in activa-
tion of the complement factor 3 (C3), the
central step in complement activation.
The C3 convertase (C3bBb) converts
the inactive yet abundant C3 component
into the biologically active effector frag-
ments referred to as anaphylatoxins
(C3a and C3b). C3a in turn binds its
G-protein-coupled receptor, C3aR, on
the surface of cells, whereas C3b can
either bind its receptor, CD46, or bind to
more of the C3 convertase, creating theC5 convertase [C3(H2O)BbP3b], which
leads to the generation of C5a and C5b.
C5b initiates the terminal enzymatic
cascade of the lytic membrane attack
complex, which mediates lysis of patho-
gens and unprotected host cells.
Although liver-generated circulating
anaphylatoxins undoubtedly play a
role in pathogen control systemically,
emerging evidence suggests that ana-
phylatoxins are also produced by immune
cells, including T cells. Once produced,
they bind their receptors on the T cell
Figure 1. Cathepsin L-dependent Intracellular and Extracellular Complement Activation
Pathways
In resting T cells, the complement factor C3 is contained intracellularly in performed stores and is proteo-
lytically cleaved to C3a and C3b, by cathepsin L within lysosomes. Intracellularly generated C3a signals
via engagement of intracellular C3aRs promote cell survival via mTOR activation. Unstimulated T cells
do not express surface C3, C3a, C3b, the C3aR, or cathepsin L. However, upon engagement of the
TCR alone or the TCR plus CD46, T cells release C3, C3a, and C3b, as well as cathepsin L and express
surface C3aR. On the cell surface, cathepsin L cleaves C3 to generate C3a and C3b. Subsequent binding
of C3a to C3ar and C3b to CD46 induces T cell secretion of cytokines such as IFN-g and IL-17A.
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Previewssurfaceand regulate adaptive Tcell immu-
nity (Heeger and Kemper, 2012; Cardone
et al., 2010). However, to date, the exact
mechanism(s) governing anaphylatoxin
production in T cells are not well under-
stood. In pursuit of the mechanism by
which C3a is released from human
T cells, Liszewski et al. (2013) speculated
that T cell-intrinsic mechanisms might
be regulating the rapid release of the
C3-cleavage product C3a. Based on their
observation that a series of endosomal or
lysosomal proteases were expressed in
T cells, they first explored whether these
cathepsins (B, G, L), might play a role
in cleavage of C3 into C3a and C3b in
human T cells. They found that cathepsin
L (CTSL), but no other cathepsin, cleaved
C3 into its active fragments (C3a,
C3b). Interestingly, the other cathepsins
degraded C3 without generation of bio-
logically active C3a and C3b—suggesting
specificity of CTSL for this reaction. Simi-
larly, CTSL-dependent cleavage appears
to be specific to C3 and C4, because
CTSLdoesnot cleaveC5 into its activation
fragments. In support of an interaction
between CTSL and C3 and C3a in intact
cells, they demonstrated that CTSL andC3 colocalized to lysosomal compart-
ments and that inhibition of CTSL activity
with a cell-permeable CTSL inhibitor
reduced intracellular levels of C3a. These
results suggested that CTSL generates
‘‘tonic’’ C3a from intracellular pools of C3
in resting T cells. Because neither the
C3aRnor theC3b receptor CD46were ex-
pressed on resting T cells, the functional
consequence of producingC3a intracellu-
larly was unclear. However, the authors
gained an important clue to the potential
function when they noted that the C3aR
was colocalized with C3 in lysosomes.
Based on the proximity between the C3a
and its receptor C3aR intracellularly, they
proposed a scenario in which CTSL
cleaves C3 into C3a and C3b and C3a in
turn binds its receptor intracellularly to
regulate basal T cell function (Figure 1).
Because C3aR engagement on CD4+
T cells activates the kinase mTOR, which
is required for T cell survival in vivo
(Strainic et al., 2008), they tested the
hypothesis that intracellular C3a-C3aR
engagement mediated mTOR and resting
T cell survival. Indeed, CTSL inhibition
and small interfering RNA (siRNA) knock-
down of C3aR in resting T cells resultedImmunity 39, Dein reduced mTOR phosphorylation and
reduced T cell viability. Although the exact
logistics of C3a-C3aR engagement were
not elucidated, these results suggest
the intriguing possibility that C3a en-
gages its G protein coupled receptor,
C3aR, on the surface of intracellular lyso-
somes, not on the plasma membrane.
These fascinating findings suggest a new
pathway of enzymatic cleavage of C3,
challenging the traditionally held belief
that complement activation only occurs
through a series of serum convertases.
To explore whether C3mediates similar
processes in activated T cells, the authors
examined the levels and cellular localiza-
tion of C3, C3a, and C3aR upon TCR acti-
vation. They show that TCR activation
induces shuttling of the intracellular
stores of C3aR to the cell surface and
amplifies intracellular CTSL-mediated
cleavage of C3 into C3a and C3b and in-
duces extracellular, cell surface CTSL-
mediated C3 activation. Subsequent
extracellular C3aR and CD46 engage-
ment by C3a and C3b, respectively, leads
to induction of the T helper 1 (Th1) cell
cytokine, interferon-g (IFN-g), and tumor
necrosis factor-a (TNF-a) (Figure 1).
CTSL inhibition of TCR-activated T cells
results in a reduction in the secretion of
the Th1 cell cytokines, IFN-g and TNF-a,
and interleukin-17A (IL-17A), whereas it
had no effect on Th2 cell cytokine pro-
duction. This sequence of events is
consistent with the lack of robust Th1
cell responses in CD46- and C3-deficient
patients (Le Friec et al., 2012). Interest-
ingly, this phenomenon was not observed
in CTSL-deficient mice in which CTSL
was maintained only in thymic epithelium,
suggesting that mouse and human cells
might differ in regards to the role of
CTSL regulation of C3 cleavage. This
species difference in CTSL regulation of
C3a-C3aR might explain some of the
conflicting reports of C3aR expression
on mouse T cells. The differential expres-
sion of the C3aR between resting and
activated T cells appears to represent a
fail-safe mechanism designed to prevent
unnecessary complement activation in
the absence of pathogens, but at the
same time allows maintenance of a sup-
ply of resting T cells that can be called
into action if necessary. This elaborate
rheostat mimics the protective mecha-
nisms utilized to protect host cells against
serum complement activation products.cember 12, 2013 ª2013 Elsevier Inc. 1001
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PreviewsBecause T cell hyperactivation and
aberrant complement activation are
prominent features of several autoim-
mune disorders, the authors sought
to determine whether modulation of
cathepsin L pathways normalized T cell
cytokine production in T cells from pa-
tients with autoimmune arthritis. Strik-
ingly, they found that intracellular C3a
levels, mTOR activity, and IFN-g levels
were higher in blood T cells from patients
with autoimmune arthritis as compared to
those obtained from healthy individuals.
Importantly, pharmacological targeting
of CTSL reversed the heightened IFN-g
production observed in the patient’s
T cells. The normalization of their IFN-g
productive capacity was accompanied
with a reduction in intracellular C3a levels
and mTOR activity. Although these
findings will need to be confirmed in a
larger study, the insights afforded by this
study raise the possibility that aberrant
regulation of the steps involved in intra-
cellular C3 activation might underlie
susceptibility to autoimmune arthritis.
More broadly, these findings have impli-
cations for a wide spectrum of human
disorders associated with complement
dysregulation, including other autoim-
mune diseases, sepsis, age-related mac-
ular degeneration, graft rejection, and
asthma, to name a few.
The current study highlights a role for
CTSL-dependent C3a-driven production
of the Th1 cell cytokines. Although these
studies suggest that CTSL-mediated
C3a generation is specifically associated
with enhanced Th1 cells and IFN-g pro-
duction, other studies have shown that
C3a regulates the production of the signa-
ture cytokines of other CD4+ T cell sub-
sets such as Th17 (Lajoie et al., 2010)
and Th2 cells (Zhang and Ko¨hl, 2010).
Studies have also shown that T regulatory1002 Immunity 39, December 12, 2013 ª201(Treg) cells express C3aR and C5aR and
that signaling through these receptors
inhibits Foxp3+ expression and Treg cell
function (Strainic et al., 2013). Moreover,
blockade of these complement pathways
in both mouse and human CD4+ T cells
favored their transformation to Foxp3+
Treg cells and as a consequence limits
the clinical expression of graft-versus-
host disease (van der Touw et al., 2013).
The known ability of Treg cells to sup-
press the expansion and cytokine pro-
duction of other CD4+ T cell subsets
suggests that the effect of C3a blockade
on IFN-g levels in autoimmune arthritis
patients might be secondary to C3aR-
mediated suppression of Treg cell cyto-
kine production and function.
Evidence supporting the conceptual
model that intracellular T cell production
of C3 and C3a occurs independently of
that generated in the liver was provided
by the observation that T cells derived
from C3-deficient patients, which do not
have measurable serum C3 or C3a levels,
contain both C3 messenger RNA (mRNA)
and C3a protein. Although the T cells from
all the patients examined contained C3a
proteins, the levels were variable between
patients and appeared to be dependent
upon specific genetic polymorphisms in
the respective C3 genes. These results
highlight the possibility that previous
assumptions made about the role of C3
in immunoregulation, which were based
on serum complement component defi-
ciencies in humans, might need to be
reevaluated.
Although pursuit of CTSL and C3 path-
ways as therapeutic targets for the treat-
ment of T cell-mediated disorders is a
tempting option, much remains to be
learned about the role of intracellular
activation of C3 in T cell-mediated disor-
ders. For example, it remains to be3 Elsevier Inc.shown whether enhanced T cell survival
and cytokine production of T cells from
autoimmune patients and/or other com-
plement-associated diseases is due to
enhanced basal T cell expression of C3
or to enhanced CTSL cleavage of C3
into C3a. It also remains to be determined
whether specific SNPs in C3 preferentially
render it susceptible or resistant to CTSL-
mediated cleavage. These results will un-
doubtedly fuel further investigation into
the role of dysregulated CTSL-mediated
intracellular C3 activation in health and
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